GILDGilead SciencesRunning, no new patients
Study of Sacituzumab Govitecan in Patients With Solid Tumor
Solid Tumor
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 53 (final count)
- Started
- Oct 12, 2021
- Main results expected
- Oct 2026
- Fully finished
- Oct 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) By Investigator Assessment
Measured over: Up to 4 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05119907 · record last updated 2025-11-17 · checked 2026-11-09 15:47 UTC